PetMed Express, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $38.2M
- Price
- $1.77
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.12%
- Volume
- 40.1K
Quote data as of 6:42 PM ET
About
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
Quick stats
Shares outstanding21.4M
Computed float17.9M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001040130
Websitehttps://www.1800petmeds.com
AI Summary
AI-generated23d agomajorbearishearningsPetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
PetMeds reported a difficult fiscal 2026, with full-year revenue falling 21.1% to $179 million and a net loss widening to $57.3 million, driven largely by a $26.7 million goodwill impairment charge.
The company rejected two unsolicited acquisition proposals ranging from $4.00 to $4.25 per share, opting to continue as an independent entity despite significant operational headwinds and a declining cost structure.
Cash reserves stand at $21.4 million, while the company highlights a new master services agreement with Rural King and focuses on stabilizing core business operations under Interim CEO Leslie Campbell.
Red flags
- Full year revenue decline of 21.1%
- Net loss widened significantly to $57.3M due to $26.7M goodwill impairment
- Rejected unsolicited buyout offers at $4.00-$4.25/share
- Whistleblower investigation costs cited as a factor in increased professional fees
- Cash position of $21.4M may be tight given operating losses